Comparative Pharmacology
Head-to-head clinical analysis: ZANTAC 25 versus ZANTAC 75.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ZANTAC 25 versus ZANTAC 75.
ZANTAC 25 vs ZANTAC 75
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive histamine H2-receptor antagonist that inhibits gastric acid secretion by blocking H2 receptors on parietal cells, reducing both basal and stimulated acid production.
Competitive inhibitor of histamine at H2 receptors on gastric parietal cells, reducing basal and stimulated gastric acid secretion.
Ranitidine 150 mg orally twice daily or 50 mg intravenously every 6-8 hours.
75 mg orally once daily or 150 mg orally once daily for heartburn; up to 300 mg/day for duodenal ulcer or GERD.
None Documented
None Documented
Terminal elimination half-life: 2.5-3.0 hours (normal renal function); prolonged to 4-5 hours in elderly and up to 6-8 hours in severe renal impairment (CrCl <30 mL/min).
Terminal elimination half-life is 2.5-3 hours. In elderly patients or those with renal impairment (CrCl <50 mL/min), half-life may extend to 4-6 hours, requiring dose adjustment.
Renal: 70% unchanged via tubular secretion; fecal: 30% as metabolites (N-oxide, S-oxide, desmethyl).
Renal (60-70% as unchanged drug), hepatic metabolism (30-40% as N-oxide, S-oxide, and desmethyl metabolites), with fecal excretion accounting for <10%.
Category C
Category C
H2 Antagonist
H2 Antagonist